Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.
